Nutrition Beverage Tolerance Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Livermore, California, United States, 94551
- The National Food Lab
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subject ≥ 45 years of age.
If female, subject is either postmenopausal for at least 1 year or surgically sterile
Subject reports that he/she has not participated in a research study in the last three months.
Exclusion Criteria:
Subject has active metabolic or endocrine disease
Subject has an autoimmune disorder
Subject has a disorder of gastrointestinal tract or any gastrointestinal surgery in past 12 months.
Subject has food allergy, celiac disease or intolerance to any of the ingredients in the study products
Subject reports history of parasthesia; and/or is currently taking medication/dietary supplements/substances that may cause parasthesia for 4 weeks prior to screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Nutritional Beverage #2
Nutritional Beverage with an amino acid Oral 237 ml
|
Nutritional Beverage Oral 237mL
Nutritional Beverage Oral 237 mL
|
|
Experimental: Nutritional Beverage #3
Nutritional Beverage with an amino acid Oral 237 ml
|
Nutritional Beverage Oral 237mL
Nutritional Beverage Oral 237 mL
|
|
Placebo Comparator: Nutritional Beverage #1
Nutritional Beverage Oral 237 ml
|
Nutritional Beverage Oral 237mL
Nutritional Beverage Oral 237 mL
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of subjects experiencing neurologic adverse event(s)
Time Frame: 2-3 weeks
|
2-3 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of subjects experiencing any adverse event(s).
Time Frame: 2-3 Weeks
|
2-3 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Vikkie Mustad, PhD, Abbott
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- BK98
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Volunteers
-
NCT02922933CompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human Volunteers
-
NCT02922946CompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human Volunteers
-
NCT01445860Completed
-
NCT00526968Completed
-
NCT01776437CompletedHuman Volunteers
-
NCT03093506Completed
-
NCT01468714Completed
Clinical Trials on Nutritional Beverage
-
NCT01355601TerminatedLearning | Concentration
-
NCT01177605Completed
-
NCT02257801Completed
-
NCT01174134CompletedLevels of DHA in the Blood
-
NCT02053506CompletedMitigation of Immune Function Decrements in Response to Stress
-
NCT01850134Withdrawn
-
NCT02405494Completed
-
NCT02449577CompletedInsulin Resistance | Alcohol Consumption